Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Olmesartan Medoxomil Intermediates With High Quality: 4,5-Dimethyl-1,3-Dioxol-2-One (DMDO) CAS 37830-90-3 4-Chloromethyl-5-Methyl-1,3-Dioxol-2-One (DMDO-Cl) CAS 80841-78-7 Ethyl 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylate CAS 144689-93-0 Diethyl 2-Propyl-1H-Imidazole-4,5-Dicarboxylate CAS 144689-94-1 Trityl Olmesartan Ethyl Ester CAS 144690-33-5 Trityl Olmesartan Acid CAS 761404-85-7 N2-Trityl Olmesartan Acid CAS 752179-89-8 Trityl Olmesartan Medoxomil CAS 144690-92-6 Olmesartan Medoxomil CAS 144689-63-4| Item | Specifications |
| Appearance | White to Off-White Powder |
| Purity / Analysis Method | >98.0% (HPLC) |
| Loss on Drying | <1.00% |
| Residue on Ignition | <0.50% |
| Single Impurity | <1.00% |
| Total Impurities | <2.00% |
| Heavy Metals (as Pb) | <20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Olmesartan Medoxomil (CAS: 144689-63-4) |
Description:
Specifications:
Package & Storage:
| Chemical Name | N2-Trityl Olmesartan Acid |
| Synonyms | Trityl Olmesartan Acid (N2); Olmesartan N2-Trityl Impurity; 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-1-[[2'-[2-(triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-Imidazole-5-Carboxylic Acid; 4-(2-Hydroxypropan-2-yl)-2-Propyl-1-((2'-(2-trityl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-Imidazole-5-Carboxylic Acid |
| CAS Number | 752179-89-8 |
| CAT Number | RF-PI1876 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C43H40N6O3 |
| Molecular Weight | 688.82 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
N2-Trityl Olmesartan Acid (CAS: 752179-89-8) is an intermediate in the synthesis of Olmesartan Medoxomil (CAS: 144689-63-4) related compounds. Olmesartan Medoxomil is an angiotensin II receptor antagonist which has been used for the treatment of high blood pressure. Olmesartan Medoxomil is a prodrug of Olmesartan, is an angiotensin II type 1 receptor (AT1) inhibitor that inhibits negative regulatory feedback on renin secretion, decreasing secretion of aldosterone and resulting in decreased peripheral vascular resistance (vasodilation). This compound exhibits antihypertensive, cardioprotective, vasodilatory, and anti-inflammatory activities. Olmesartan Medoxomil may be used alone or in combination with other antihypertensive agents. In comparative clinical studies in patients with essential hypertension, Olmesartan reduced sitting cuff diastolic blood pressure significantly more than Losartan, Valdesartan and Ibesartan, while reductions in systolic blood pressure were similar for all treatments.
